Oncocyte Corp Files 8-K on Financials
Ticker: IMDX · Form: 8-K · Filed: Mar 24, 2025 · CIK: 1642380
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Oncocyte Corp dropped an 8-K on March 24th about their financials. Check it out.
AI Summary
On March 24, 2025, Oncocyte Corporation filed an 8-K report detailing results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 15 Cushing, Irvine, California.
Why It Matters
This filing provides crucial updates on Oncocyte Corporation's financial performance and operational status, which is important for investors and stakeholders to assess the company's health.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for financial reporting and does not indicate any unusual or high-risk events.
Key Players & Entities
- Oncocyte Corporation (company) — Registrant
- March 24, 2025 (date) — Date of Report
- 15 Cushing, Irvine, California 92618 (address) — Principal executive offices
- 949-409-7600 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition of Oncocyte Corporation, and it includes Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on March 24, 2025.
What is Oncocyte Corporation's principal executive office address?
Oncocyte Corporation's principal executive office is located at 15 Cushing, Irvine, California 92618.
What is the IRS Employer Identification Number (EIN) for Oncocyte Corporation?
The IRS Employer Identification Number (EIN) for Oncocyte Corporation is 27-1041563.
What is the SIC code for Oncocyte Corporation?
The Standard Industrial Classification (SIC) code for Oncocyte Corporation is 2835, which corresponds to IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 24, 2025 regarding Oncocyte Corp (IMDX).